The story has been updated to include comments from Qiagen's conference call on Wednesday morning.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market on Tuesday that its second quarter sales rose 5 percent year over year, matching consensus analysts' estimates on the top and bottom lines.

Qiagen recorded sales of $330.8 million, up from $315.2 million during the year-ago quarter, and on par with the average Wall Street estimate. It said that its adjusted net sales were $331.2 million, up 5 percent from $316.4 million for Q2 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.